6th Annual Oligonucleotides for CNS Summit
8.19 – 8.21, 2026 | Boston, MA, USA
Latest Events & Articles
6th Annual Oligonucleotides for CNS Summit
-
5th Annual Oligonucleotides CMC & Analytical Development Summit
8.17 – 8.19, 2026 | Boston, MA, USA
-
3rd Annual mRNA CONFERENCE EUROPE 2026
7.22 – 7.23, 2026 | Frankfurt, Germany
-
6th mRNA‑Based Therapeutics Summit
7.20 – 7.22, 2026 | Boston, MA, USA
-
6th Annual RNA Therapeutics Conference
6.24 – 6.26, 2026 | Worcester, MA, USA
-
CPHI China 2026
6.16 – 6.18, 2026 | Shanghai, China
-
SAPA-NE 28th Annual Conference
6.13, 2026 | Boston, MA, USA
-
IOPC 2026
6.09 – 6.11, 2026 | Athens, Greece
-
TIDES USA 2026
5.11 – 5.14, 2026 | Boston, MA, USA
-
ASGCT Annual Meeting 2026
5.11 – 5.15, 2026 | Boston, MA, USA
-
The 3rd CRISPR MEDiCiNE Conference
4.14 – 4.16, 2026 | Copenhagen, Denmark
-
11th Annual OPT Congress
3.18 – 3.19, 2026 | Boston, MA, USA
-
RNA Leader Europe 2026
3.17 – 3.19, 2026 | Austria Center, Vienna, Austria
Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support of SiranBio’s Dual-Target siRNA Program
Introduction Singapore, 5 May 2026: Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end...
-
Hongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw Materials
Introduction In Singapore, January 12, 2026; Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use in mRNA...
-
Hongene to supply exNA oligonucleotide technology under new licensing deal
SINGAPORE (August 26th, 2025) – Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, today entered a non-exclusive licensing agreement with the UMass Chan...
-
Pioneering LNP Expert Dr. Pieter Cullis Joins Hongene’s Scientific Advisory Board
SINGAPORE (August 5th, 2025) – Hongene, a global CDMO focused on nucleic acid raw materials and medicines, has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle (LNP) drug...
-
Hongene Supports Clinical Advancement of siRNA DNV001 Using Proprietary Chemoenzymatic Ligation Platform
Introduction SINGAPORE (July 10th, 2025) – Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, today announced its critical role in advancing DNV001, a...
-
Hongene Launches Operations at its New mRNA CDMO GMP Facility
Hongene launches operations at its new mRNA CDMO GMP facility, ensuring efficient, high-quality production of mRNA therapeutics and vaccines. The new facility consists of more than 30,000 sq. ft. of...
-
Deepening Cooperation in the Oligo Therapeutics Field: Hongene Biotech and Syensqo Sign Strategic Cooperation Agreement
NEWS Recently, at Hongene Biotech's high-tech GMP facility, Hongene Biotech and Syensqo officially signed a strategic cooperation framework agreement. This milestone event signifies that both parties will engage in deeper...
-
Hongene Biotech Corporation and ReciBioPharm establish a gene editing development partnership
0800 AM Eastern on Monday 9th September – Hongene Biotech Corporation, a global leader in nucleic acid manufacturing, and ReciBioPharm, a leading advanced therapeutics CDMO services provider, have announced a strategic...
-
Hongene Partners with n-Lorem to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients
SAN DIEGO, Calif., April 24, 2024 (BUSINESS WIRE), Hongene Biotech Corporation, a global specialist in nucleic acid raw material supply and CDMO services, and n-Lorem, a nonprofit foundation formed a new partnership to support...
-
Hongene Launches Operations at its New mRNA CDMO GMP Facility
Hongene launches operations at its new mRNA CDMO GMP facility, ensuring efficient, high-quality production of mRNA therapeutics and vaccines. The new facility consists of more than 30,000 sq. ft. of...
-
Hongene Expands Phosphoramidite Production Capability to 58 tons
Hongene has expanded its the expansion of its phosphoramidite and nucleotide production capabilities with the launch of operations at its new Manufacturing Facility No.2 in Shanghai, China. The new facility...
Reducing Risk in Nucleic Acid Therapeutics: The Case for Vertical Integration
Demand for nucleic acid therapeutics (NATs) is increasing as mRNA-based products, oligonucleotide therapeutics and gene editing applications expand from niche rare diseases into mainstream, high-prevalence indications. An example of this...
-
Built to Scale, Chemoenzymatic Ligation Takes RNA Therapeutics from Lab to Clinic
Developing new RNA therapeutics requires years of dedicated effort. However, taking a program from the promise of preclinical models into the reality of clinical development presents the fundamental challenge of...
-
Breaking Through Synthesis Challenges: Hongene Accelerates Clinical Translation of Dual-Targeting Oligonucleotide Drugs!
In recent years, dual-targeting oligonucleotide drugs have become one of the hottest fields in the global pharmaceutical industry due to their advantages of synergistic effects and avoiding combination therapy. Despite...
-
The Hidden Costs of Fragmented Supply Chains in Nucleic Acid Therapeutics
The rise of nucleic acid therapeutics (NATs) — including oligonucleotides such as siRNA, mRNA-based products, and CRISPR-based drugs — is transforming modern medicine. These precise and potent modalities are advancing...
-
Ushering in a New Era of Lipid Management – Hongene Empowers Oligo Theraputics to Expand into Metabolic Diseases
Hypercholesterolemia is one of the most common chronic metabolic disorders. Its core characteristic is abnormally elevated levels of "bad cholesterol," or low-density lipoprotein cholesterol (LDL-C), which can form atherosclerotic plaques...
-
Enzymatic Ligation Synthesis Technology Application Case Study (Part 2): High-Fidelity sgRNA Synthesis
Introduction The widespread application of CRISPR-Cas technology in the gene editing field is driving rapid growth in the demand for sgRNA synthesis. However, the traditional SPOS (Solid-Phase Oligonucleotide Synthesis) method...
-
Case Study on the Application of Enzymatic Ligation Synthesis Technology (Part 1): High-Purity Synthesis of Bivalent siRNA
Introduction siRNA, as a type of RNA interference (RNAi) technology, has demonstrated significant value and potential in the fields of gene silencing and targeted therapy. During the development of siRNA...
-
Chemoenzymatic Synthesis of siRNA and sgRNA Using Ligation Technology
Advancements in RNA therapeutics are increasing the demand for high-quality synthetic oligonucleotides including siRNA (small interfering RNA) and sgRNA (single guide RNA). While conventional solid-phase oligonucleotide synthesis (SPOS) remains the...
-
Innovative Improvements in P(V) Oligonucleotide Synthesis Platform, Empowering Oligonucleotide Drug Development!
Introduction December 9, 2024 – A research team led by Professor Phil S. Baran from Scripps Research in the United States, in collaboration with researchers from Elsie Biotechnologies and Hongene...
-
Analysis of Core Materials and Process Strategies for Nucleic Acid Drugs
Introduction Nucleic acid drugs, including small nucleic acids and mRNA drugs, represent a rapidly growing segment within the biopharmaceutical field. With continuous technological iterations, particularly innovations in nucleic acid chemical...
Chemoenzymatic Ligation: Advancing Next-Generation Manufacturing Technologies for siRNA and sgRNA
As several siRNA therapeutics move toward regulatory approval for cardiometabolic diseases, we expect demand for large-scale manufacturing to grow sharply over the coming decade. At TIDES Europe 2025 in Basel,...
-
Chemoenzymatic ligation comes of age: A present-day solution for scalable manufacturing for siRNA and sgRNA drugs
As the market demand for RNA therapeutics such as siRNA and sgRNA is anticipated to grow substantially over the next decade, there is a need for scalable, cost-effective, and sustainable...
-
The Evolving Landscape of Oligonuecleotide Manufacturing-Meeting Future Demand with Ligation Technologies
As several siRNA assets indicated for treating diseases associated with cardiovascular targets advance toward potential approval, the market demand for high-quality oligonucleotides is anticipated to grow substantially over the next...
